Fibroblast growth factor 21: a novel biomarker for human muscle-manifesting mitochondrial disorders

Bibliography

• Ylikallio E, Suomalainen A. Mechanisms of mitochondrial diseases. Ann Med 2011;44:41-59
   PubMed Web of Science ®Google Scholar
• Suomalainen A. Biomarkers for mitochondrial respiratory chain disorders. J Inherit Metab Dis 2011;34:277-82
   PubMed Web of Science ®Google Scholar
• Götz A, Isohanni P, Pihko H, et al. Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndrome. Brain 2008;131:2841-50
   PubMed Web of Science ®Google Scholar
• Suomalainen A, Elo JM, Pietiläinen KH, et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 2011;10:806-18
   PubMed Web of Science ®Google Scholar
• Rustin P, Chretien D, Bourgeron T, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994;228:35-51
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627-35
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol 2009;9:805-10
   PubMed Web of Science ®Google Scholar
• Badman MK, Pissios P, Kennedy AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007;5:426-37
   PubMed Web of Science ®Google Scholar
• Tyynismaa H, Mjosund KP, Wanrooij S, et al. Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. Proc Natl Acad Sci USA 2005;102:17687-92
   PubMed Web of Science ®Google Scholar
• Suomalainen A, Majander A, Haltia M, et al. Multiple deletions of mitochondrial DNA in several tissues of a patient with severe retarded depression and familial progressive external ophthalmoplegia. J Clin Invest 1992;90:61-6
   PubMed Web of Science ®Google Scholar
• Tyynismaa H, Carroll CJ, Raimundo N, et al. Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet 2010;19:3948-58
   PubMed Web of Science ®Google Scholar
• Ahola-Erkkila S, Carroll CJ, Peltola-Mjosund K, et al. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Mol Genet 2010;19:1974-84
   PubMed Web of Science ®Google Scholar
• Li H, Dong K, Fang Q, et al. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J Hepatol 2013;58:557-63
   PubMed Web of Science ®Google Scholar
• Domingo P, Gallego-Escuredo JM, Domingo JC, et al. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010;24:2629-37
   PubMed Web of Science ®Google Scholar
• Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010;139:456-63
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Eren F, Yonal O, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010;40:887-92
   PubMed Web of Science ®Google Scholar
• Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57:1246-53
   PubMed Web of Science ®Google Scholar
• Lin Z, Wu Z, Yin X, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 2010;5:e15534
   PubMed Web of Science ®Google Scholar
• Tyynismaa H, Raivio T, Hakkarainen A, et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 2011;96:E351-5
   Web of Science ®Google Scholar
• Lin Z, Zhou Z, Liu Y, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One 2011;6:e18398
   PubMed Web of Science ®Google Scholar
• Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008;22:1006-14
   PubMed Web of Science ®Google Scholar
• Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007;282:26687-95
   PubMed Web of Science ®Google Scholar
• Badman MK, Pissios P, Kennedy AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007;5:426-37
   PubMed Web of Science ®Google Scholar
• Hotta Y, Nakamura H, Konishi M, et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 2009;150:4625-33
   PubMed Web of Science ®Google Scholar
• Potthoff MJ, Inagaki T, Satapati S, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 2009;106:10853-8
   PubMed Web of Science ®Google Scholar
• Dostálová I, Kaválková P, Haluzíková D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008;93:3627-32
   PubMed Web of Science ®Google Scholar
• Shaham O, Slate NG, Goldberger O, et al. A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells. Proc Natl Acad Sci USA 2010;107:1571-5
   PubMed Web of Science ®Google Scholar